-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on September 14, the pharmaceutical and biological sector was among the top gainers.
From the perspective of individual stocks, Qizheng Tibetan Medicine, Xingqi Eye Medicine, Hebang Bio, Jimin Medical, Tongce Medical, etc.
rose one after another
.
Among them, Jimin Medical rose rapidly during the session on September 14, with an increase of more than 2% within 5 minutes.
As of 9:36, it was reported at 15.
09 yuan, with a turnover of 20.
8642 million yuan and a turnover rate of 0.
44%
.
Jimin Medical is a modern pharmaceutical company.
The company's business covers three major sectors: medical and health services, medical devices and chemical pharmaceuticals.
In the medical device sector, it has two wholly-owned subsidiaries, Jumin Bio and Spain LINEAR.
The products developed and produced mainly include: Injection and puncture equipment series products, in vitro diagnostic series products and hemodialysis series products
.
In the first half of the year, the company's net profit increased by 2824%, which the company attributed to the substantial increase in the profit of the medical device segment
.
Hebang Bio rose rapidly in the intraday, with an increase of more than 2% in 5 minutes.
As of 9:41, it was reported at 4.
22 yuan, with a turnover of 393 million yuan and a turnover rate of 1.
08%
.
On the news, recently, due to the suspension of production of glyphosate by overseas pharmaceutical giants, the price has risen sharply and the supply is tight.
Hebang Bio's glyphosate products account for about 60% of the revenue.
It has advantages in various aspects such as quality and cost.
The 2021 interim report shows that the company's net profit in the first half of the year was 914 million yuan, a year-on-year increase of 19 times
.
It is understood that in addition to Hebang Bio, Winbond Health, Jiangshan Shares, Xin'an Shares, etc.
have also benefited from the increase in glyphosate prices and have received financial attention
.
Xingqi ophthalmic medicine rose rapidly in the intraday market, with an increase of more than 2% in 5 minutes.
As of 9:44, it was reported at 108.
99 yuan, with a turnover of 51.
5869 million yuan and a turnover rate of 0.
79%
.
The analysis believes that the reason for the change in the stock is: the company is mainly engaged in the research and development of ophthalmic drugs, including ophthalmic anti-infective drugs, ophthalmic anti-inflammatory/anti-infective drugs, mydriatic drugs and cycloplegic drugs, and ophthalmic non-steroidal anti-inflammatory drugs.
Ophthalmology prescription drugs such as miotic drugs and anti-glaucoma drugs, in addition, ophthalmic preparation products represented by products such as "Di Keluo", "Di Fei", "Di Shan" and "Sugao Jie" have established themselves in the industry.
Good brand reputation
.
Tongce Medical rose rapidly in the intraday market, with an increase of more than 2% within 5 minutes.
As of 9:46, it was reported at 250.
06 yuan, with a turnover of 268 million yuan and a turnover rate of 0.
34%
.
Tongce Medical is a domestic chain of dental medical giants.
The company continues to develop professional medical services in the fields of oral, reproductive and ophthalmology.
It has oral medical institutions and assisted reproductive medical institutions.
Among them, in the oral field, as a large-scale oral medical group in China, it has opened all over the country.
32 dental hospitals
.
In the first half of the year, the company's main income was 1.
318 billion yuan, a year-on-year increase of 74.
81%; the net profit attributable to the parent was 351 million yuan, a year-on-year increase of 141.
16%
.
Qizheng Tibetan Medicine rose rapidly in intraday trading, with an increase of more than 2% within 5 minutes.
As of 9:49, it was reported at 32.
47 yuan, with a turnover of 41.
0374 million yuan and a turnover rate of 0.
25%
.
The company's main business is the research and development, production and sales of Tibetan medicines.
The company's operating income in the first half of the year was 781.
4726 million yuan, a year-on-year increase of 27.
69%; the net profit attributable to shareholders of the listed company was 988.
5984 million yuan, a year-on-year increase of 346.
88%
.
According to public information, the net profit of Qizheng Tibetan Medicine has grown steadily in the past 10 years
.
The semi-annual report pointed out that during the reporting period, the company's substantial increase in profit under the equity method was mainly due to the listing of Qingdao Baheal Pharmaceuticals, which was invested by Tibet Qunying Investment Center (Limited Partnership), a merger and acquisition fund established by the company
.
From the perspective of individual stocks, Qizheng Tibetan Medicine, Xingqi Eye Medicine, Hebang Bio, Jimin Medical, Tongce Medical, etc.
rose one after another
.
Among them, Jimin Medical rose rapidly during the session on September 14, with an increase of more than 2% within 5 minutes.
As of 9:36, it was reported at 15.
09 yuan, with a turnover of 20.
8642 million yuan and a turnover rate of 0.
44%
.
Jimin Medical is a modern pharmaceutical company.
The company's business covers three major sectors: medical and health services, medical devices and chemical pharmaceuticals.
In the medical device sector, it has two wholly-owned subsidiaries, Jumin Bio and Spain LINEAR.
The products developed and produced mainly include: Injection and puncture equipment series products, in vitro diagnostic series products and hemodialysis series products
.
In the first half of the year, the company's net profit increased by 2824%, which the company attributed to the substantial increase in the profit of the medical device segment
.
Hebang Bio rose rapidly in the intraday, with an increase of more than 2% in 5 minutes.
As of 9:41, it was reported at 4.
22 yuan, with a turnover of 393 million yuan and a turnover rate of 1.
08%
.
On the news, recently, due to the suspension of production of glyphosate by overseas pharmaceutical giants, the price has risen sharply and the supply is tight.
Hebang Bio's glyphosate products account for about 60% of the revenue.
It has advantages in various aspects such as quality and cost.
The 2021 interim report shows that the company's net profit in the first half of the year was 914 million yuan, a year-on-year increase of 19 times
.
It is understood that in addition to Hebang Bio, Winbond Health, Jiangshan Shares, Xin'an Shares, etc.
have also benefited from the increase in glyphosate prices and have received financial attention
.
Xingqi ophthalmic medicine rose rapidly in the intraday market, with an increase of more than 2% in 5 minutes.
As of 9:44, it was reported at 108.
99 yuan, with a turnover of 51.
5869 million yuan and a turnover rate of 0.
79%
.
The analysis believes that the reason for the change in the stock is: the company is mainly engaged in the research and development of ophthalmic drugs, including ophthalmic anti-infective drugs, ophthalmic anti-inflammatory/anti-infective drugs, mydriatic drugs and cycloplegic drugs, and ophthalmic non-steroidal anti-inflammatory drugs.
Ophthalmology prescription drugs such as miotic drugs and anti-glaucoma drugs, in addition, ophthalmic preparation products represented by products such as "Di Keluo", "Di Fei", "Di Shan" and "Sugao Jie" have established themselves in the industry.
Good brand reputation
.
Tongce Medical rose rapidly in the intraday market, with an increase of more than 2% within 5 minutes.
As of 9:46, it was reported at 250.
06 yuan, with a turnover of 268 million yuan and a turnover rate of 0.
34%
.
Tongce Medical is a domestic chain of dental medical giants.
The company continues to develop professional medical services in the fields of oral, reproductive and ophthalmology.
It has oral medical institutions and assisted reproductive medical institutions.
Among them, in the oral field, as a large-scale oral medical group in China, it has opened all over the country.
32 dental hospitals
.
In the first half of the year, the company's main income was 1.
318 billion yuan, a year-on-year increase of 74.
81%; the net profit attributable to the parent was 351 million yuan, a year-on-year increase of 141.
16%
.
Qizheng Tibetan Medicine rose rapidly in intraday trading, with an increase of more than 2% within 5 minutes.
As of 9:49, it was reported at 32.
47 yuan, with a turnover of 41.
0374 million yuan and a turnover rate of 0.
25%
.
The company's main business is the research and development, production and sales of Tibetan medicines.
The company's operating income in the first half of the year was 781.
4726 million yuan, a year-on-year increase of 27.
69%; the net profit attributable to shareholders of the listed company was 988.
5984 million yuan, a year-on-year increase of 346.
88%
.
According to public information, the net profit of Qizheng Tibetan Medicine has grown steadily in the past 10 years
.
The semi-annual report pointed out that during the reporting period, the company's substantial increase in profit under the equity method was mainly due to the listing of Qingdao Baheal Pharmaceuticals, which was invested by Tibet Qunying Investment Center (Limited Partnership), a merger and acquisition fund established by the company
.
